According to a study presented on 18 June at the annual conference of theEndocrine Society in San Francisco, kisspeptin, a natural hormone, is able to "restore the rate of secretion of GnRH and the ovulation cycles." It is better tolerated than the fertility drugs used today to stimulate ovulation, "which expose nearly one woman out of 100 to ovarian hyperstimulation syndrome (OHSS)."
The British team carried out the study on 30 women, the results were positive for 29 of them, and the ovules of 28 of them were able to be used for IVF [in-vitro fertilization]. Eight weeks ago, in London, "the first baby was born with this inducer of ovulation." The team of researchers is awaiting "the end of this small-scale study due in the summer before testing the molecule on a larger scale with patients at risk of OHSS." But Prof. Richard Fleming, an expert from the British Fertility Society, says that it is "too early to recommend kisspeptin routinely as more trials were needed" and "in all likelihood we will have to wait several years for this new treatment to become widely available."
Editor’s note: Could this hormone not be used to restore the ovulation of anovular women wishing to become pregnant, without using in-vitro fertilization?